Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $3.9 billion, reflecting a 3% year-over-year increase, driven by higher collaboration revenue and strong sales growth of Dupixent, EYLEA HD, and Libtayo [40][41] - Diluted net income per share was $11.44, with net income of $1.2 billion [40] - Regeneron's share of collaboration profits from Sanofi grew 42% year-over-year, primarily due to Dupixent [41] Business Line Data and Key Metrics Changes - Global net product sales for Dupixent reached $4.9 billion in Q4 2025, a 32% increase year-over-year [7] - Libtayo's global net sales were $425 million in Q4 2025, up 13% year-over-year [37] - EYLEA HD net product sales in the U.S. were $506 million in Q4 2025, representing a 66% increase [9] Market Data and Key Metrics Changes - Dupixent is now approved in eight indications, with over 1.4 million patients on therapy globally, indicating significant market penetration potential [7] - EYLEA HD has become a growing proportion of Regeneron's total anti-VEGF franchise, contributing nearly half of total net sales [33] - Libtayo is recognized as the leading immunotherapy for advanced non-melanoma skin cancers, with strong demand growth across all approved indications [37] Company Strategy and Development Direction - Regeneron anticipates at least four FDA approvals in 2026, including three for new molecular entities and one for the EYLEA HD prefilled syringe [11] - The company plans to initiate 18 additional phase 3 studies, targeting approximately 35,000 patients over multiple years [13] - Regeneron aims to continue capital deployment for share repurchases, dividends, and complementary business development to drive long-term shareholder value [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about reaching an agreement with the U.S. government to reduce drug costs while ensuring access to innovative treatments [11] - The company highlighted the importance of its innovative pipeline, with multiple pivotal readouts and regulatory milestones expected in 2026 [30] - Management emphasized the competitive advantages of Dupixent, including its efficacy and safety profile compared to other immunomodulators [59] Other Important Information - Regeneron generated $4.1 billion in free cash flow in 2025 and returned $3.8 billion to shareholders, primarily through share repurchases [44][45] - The company initiated a quarterly dividend, providing additional flexibility to return capital to shareholders [45] Q&A Session Summary Question: Update on Libtayo plus fianlimab readouts - Management indicated that the best estimate for advanced melanoma readout is in the first half of the year, with adjuvant timing also expected in the same timeframe [52] Question: Dupixent IP and future potential - Management refrained from providing additional comments but acknowledged Sanofi's commentary on extending the IP runway [55] Question: Frontline metastatic melanoma data and hazard ratio - Management stated that the study is powered to achieve a primary endpoint similar to the current standard of care, with hopes for better outcomes [63] Question: Broader R&D strategy and focus areas - Management confirmed a commitment to a balanced approach across therapeutic areas, driven by genetics to identify new drug opportunities [70] Question: Development of a new version of Dupixent - Management discussed the potential of a "souped-up" version of Dupixent that may offer longer-lasting effects and other advantages, with plans to move it forward in clinical development [76]

Regeneron Pharmaceuticals (NasdaqGS:REGN) Q4 2025 Earnings call January 30, 2026 08:30 AM ET Speaker4Welcome to the Regeneron Pharmaceuticals fourth quarter 2025 earnings conference call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President of Investor Relations. ...

Regeneron Corporate Presentation J A N U A R Y 2 0 2 6 2 Integrating Genetics, Proteomics, and Big Data World's largest DNA and proteomics-linked healthcare database, enabling advanced drug discovery, development, and healthcare analytics This non-promotional presentation contains investigational data as well as forward-looking statements; actual results may vary materially. Note regarding forward-looking statements and non-GAAP financial measures This presentation includes forward-looking statements that i ...

Core Viewpoint - U.S. drugmaker Regeneron Pharmaceuticals exceeded analysts' profit expectations for the fourth quarter, driven by robust demand for its eczema treatment, Dupixent [1] Company Summary - Regeneron Pharmaceuticals reported a strong performance in the fourth quarter, attributed to the high demand for its eczema treatment, Dupixent [1]

Core Insights - Regeneron Pharmaceuticals reported strong financial performance in 2025, driven by four blockbuster medicines and a promising late-stage clinical portfolio [2][3] - The company achieved significant label expansions and new approvals for its key products, including EYLEA HD and Dupixent, enhancing their commercial potential [2][4] Financial Highlights - Total revenues for Q4 2025 were $3,884 million, a 3% increase from Q4 2024, while full year revenues reached $14,343 million, up 1% from 2024 [3][14] - GAAP net income for Q4 2025 was $845 million, down 8% from Q4 2024, with a full year GAAP net income of $4,505 million, an increase of 2% [3][14] - Non-GAAP net income for Q4 2025 was $1,249 million, a decrease of 10% from Q4 2024, while full year non-GAAP net income was $4,888 million, down 8% [3][14] Business Highlights - Dupixent global net sales increased by 34% in Q4 2025 to $4.9 billion, with full year sales rising 26% to $17.8 billion [4][14] - EYLEA HD U.S. net sales surged 66% in Q4 2025 to $506 million, with full year sales increasing 36% to $1.6 billion [4][14] - Libtayo received additional approvals and is now the leading immunotherapy for non-melanoma skin cancers [2][4] Pipeline Progress - Regeneron has approximately 45 product candidates in clinical development, with several key updates expected in 2026 [4][10] - Upcoming milestones include FDA decisions for EYLEA HD pre-filled syringe and Dupixent's regulatory submissions for new indications [13][28] Capital Allocation - The company repurchased $671 million of its common stock in Q4 2025 and $3.5 billion for the full year, with $1.5 billion remaining for future repurchases [26] - A cash dividend of $0.94 per share was declared, payable on March 5, 2026 [27] 2026 Financial Guidance - Regeneron projects GAAP R&D expenses between $6.450 billion and $6.680 billion for 2026, with non-GAAP R&D expenses expected to be between $5.900 billion and $6.100 billion [28][29] - The company anticipates a GAAP effective tax rate of 12% to 14% for 2026 [28]

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.Analysts expect the Tarrytown, New York-based company to report quarterly earnings at $10.74 per share, down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals' quarterly revenue is $3.79 billion, versus $3.79 billion a year earlier, according to data from Benzinga Pro.On Dec. 1, Regeneron Pharmaceuticals and Tessera Th ...

Earnings Results - Regeneron Pharmaceuticals is set to release its fourth-quarter earnings results on January 30, with analysts expecting earnings of $10.74 per share, a decrease from $12.07 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $3.79 billion, unchanged from the previous year [1] Collaboration Announcement - On December 1, Regeneron Pharmaceuticals announced a global collaboration with Tessera Therapeutics to develop and commercialize TSRA-196 [2] - Following the announcement, Regeneron Pharmaceuticals shares experienced a slight decline of 0.2%, closing at $749.44 [2] Analyst Ratings - Benzinga provides access to the latest analyst ratings for Regeneron Pharmaceuticals, allowing readers to sort by various criteria such as stock ticker and rating change [2]

We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Regeneron Pharmaceuticals, Inc. is among the most profitable stocks. TheFly reported on January 22 that Evercore ISI increased its price target for REGN to $875 from $750 and maintained an Outperform rating on the stock. The firm expressed confidence in REGN’s updated outlook and recent pricing actions. Evercore ISI identified Dupixent and Eylea HD as key players in the company’s growth and noted that both products are well ...

Core Viewpoint - Regeneron Pharmaceuticals is a leading biotechnology company focused on developing innovative medicines for serious diseases, competing with major players like Amgen and Biogen [1] Financial Performance - Regeneron is set to release its quarterly earnings on January 30, 2026, with an estimated EPS of $10.56 and revenue of approximately $3.78 billion, while the Zacks Consensus Estimate projects revenues at $3.82 billion [2] - Historically, Regeneron has exceeded earnings estimates in three of the last four quarters, with an average surprise of 21.81% [2] Product Focus - The upcoming earnings report will emphasize profits from the asthma drug Dupixent and sales of Eylea HD, with Eylea's legacy sales declining due to competition, but Eylea HD expected to boost overall franchise revenues [3] - Strong demand for Dupixent across multiple indications is anticipated to drive solid profit growth, offsetting the decline in Eylea sales [3] Stock Performance - Regeneron's stock has increased over 16% since the last analysis, reinforcing a Buy rating, although it is still trading below its all-time high of approximately $1,200 reached in August 2024 [4] - The earnings report could potentially drive the stock price higher if results exceed expectations, while a miss might lead to a decline in stock value [4] Valuation Metrics - Regeneron has a price-to-earnings (P/E) ratio of approximately 17, indicating investors are willing to pay $17 for every $1 of earnings [5] - The company's price-to-sales ratio stands at about 5.44, and the enterprise value to sales ratio is roughly 5.46, indicating consistent valuation metrics [5] - Regeneron demonstrates a solid financial position with a low debt-to-equity ratio of 0.087 and a strong current ratio of 4.06 [5][6]

Core Insights - Investors are focusing on profits from the asthma drug Dupixent and sales of Eylea HD as Regeneron Pharmaceuticals prepares to report its fourth-quarter 2025 results on January 30, 2026, with revenue estimates at $3.82 billion and earnings at $10.56 per share [1] Earnings Performance - Regeneron has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 21.81%, including a 25.32% beat in the last reported quarter [2] Earnings Prediction - The earnings model predicts a likely earnings beat for Regeneron, supported by a positive Earnings ESP of +0.82% and a Zacks Rank of 1 (Strong Buy) [3][4] Product Sales Overview - Eylea, a key revenue driver, has faced sales pressure due to competition from Vabysmo, with preliminary sales of $577 million in the U.S. for Q4 [5][6] - Eylea HD, a higher dose version, has seen strong initial uptake with sales of $506 million in the U.S. for the quarter, following FDA approval for new dosing options [7][8] Dupixent Performance - Dupixent is expected to show solid growth in Q4, driven by strong demand across multiple indications, likely offsetting the decline in Eylea sales [10] Diversification Strategy - Regeneron is working to diversify its revenue base beyond Eylea, focusing on building its oncology franchise, which includes Libtayo and the newly approved Lynozyfic [11] - Libtayo's sales growth has been bolstered by recent label expansions, with current sales estimates at $482 million [12] Share Repurchase Program - A decrease in outstanding shares due to a $3.0 billion share repurchase program is expected to positively impact the bottom line, with $2.156 billion remaining for repurchases as of September 30, 2025 [15] Stock Performance - Regeneron's shares have increased by 12.2% over the past year, compared to the industry's growth of 17.1% [16]